default author photo

Stephen Falk

University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust

Bristol

United Kingdom

SCHOLARLY PAPERS

2

DOWNLOADS

265

TOTAL CITATIONS

1

Scholarly Papers (2)

1.

Standard Versus Dose Reduced Chemoradiotherapy in Anal Cancer: Short Term Results of the PhaseII PLATO-ACT4 Randomised Controlled Trial (RCT) ISRCTN88455282

Number of pages: 38 Posted: 04 Feb 2025
Leeds Teaching Hospitals NHS Trust, Cardiff University - Centre for Trials Research, University of Leeds - Leeds Institute of Clinical Trials Research, University College London, National Radiotherapy Trials QA (RTTQA) Group, National Radiotherapy Trials QA (RTTQA) Group, Independent, University of Leeds - Leeds Institute of Clinical Trials Research, St James’s University Hospital, University of Leeds - Leeds Institute of Clinical Trials Research, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, Government of the United Kingdom, Department of Health, National Health Service (NHS), Mount Vernon Cancer Centre Northwood, King’s College London, University College London - Department of Medical Physics and Biomedical Engineering, University Hospitals Sussex NHS Foundation Trust, Government of the United Kingdom - Oxford University Hospitals NHS Foundation Trust, NHS Foundation Trust - Royal Marsden Hospital, The University of Manchester - Manchester Cancer Research Centre, University of Leeds - Institute of Medical Research, University of Leeds, University of Leeds - Leeds Institute of Clinical Trials Research, University of Surrey, University Hospitals Sussex NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, University of Leeds - Institute of Medical Research and Mount Vernon Hospital
Downloads 187 (407,391)
Citation 1

Abstract:

Loading...

anal cancer, toxicity, chemoradiotherapy

2.

Standard or High Dose Chemoradiotherapy, with or Without the Protease Inhibitor Nelfinavir, for the Treatment of Locally Advanced Pancreatic Cancer: Efficacy, Safety and Health-Related Quality of Life Outcomes from the Multi-Centre Two Stage Phase 1/Randomised Phase 2 SCALOP-2 Study

Number of pages: 38 Posted: 29 Jan 2024
Government of the United Kingdom - Oxford University Hospitals NHS Foundation Trust, University of Oxford, University of Oxford, University of Cambridge - Department of Oncology, University College London - UCL Cancer Institute, Manchester Academic Health Sciences Centre - The Christie NHS Foundation Trust, Government of the United Kingdom - Oxford University Hospitals NHS Foundation Trust, University of Oxford - Nuffield Department of Primary Care Health Sciences, University of Oxford, University of Oxford, Velindre Cancer Centre, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, Imperial College London - Hammersmith Hospital, Department of Cancer Medicine, University of Cambridge, NHS Foundation Trust - Norfolk and Norwich University Hospital, Government of the United Kingdom - Hull University Teaching Hospitals NHS Trust, Coventry University - Coventry University Hospital, Cardiff University - Centre for Trials Research, University of Leeds - Institute of Medical Research, University of Oxford - MRC Oxford Institute for Radiation Oncology, University College London - Department of Medical Physics and Biomedical Engineering and University of Cambridge
Downloads 78 (823,616)

Abstract:

Loading...

Pancreatic cancer, Chemoradiotherapy, Nelfinavir, Dose escalation, Survival, Outcomes, Toxicity, Health-related quality of life